Related Experiment Videos
Menopausal estrogen replacement therapy and breast cancer
1Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tenn. 37232-2637.
Archives of Internal Medicine
|January 1, 1991
Summary
Low-dose estrogen replacement therapy (ERT) does not increase breast cancer risk. This meta-analysis found no significant risk elevation for women using 0.625 mg/d or less of conjugated estrogens.
Area of Science:
- Oncology
- Endocrinology
- Epidemiology
Background:
- Estrogen replacement therapy (ERT) is commonly used for menopausal symptoms.
- The relationship between ERT and breast cancer risk remains a significant public health concern.
- Previous studies have yielded conflicting results regarding ERT's impact on breast cancer incidence.
Purpose of the Study:
- To conduct a meta-analysis of existing literature on breast cancer risk associated with ERT.
- To investigate the influence of ERT dosage, duration, and type on breast cancer risk.
- To clarify the association between low-dose ERT and breast cancer incidence.
Main Methods:
- Systematic review and meta-analysis of published studies.
- Analysis of relative risk (RR) of breast cancer.
- Stratification of data by ERT dosage, duration, and patient history.
Main Results:
- The overall RR of breast cancer with ERT was 1.07, with significant heterogeneity among studies.
- Low-dose conjugated estrogens (≤0.625 mg/d) showed a non-significant RR of 1.08 (95% CI, 0.96 to 1.2).
- Higher doses (≥1.25 mg/d) showed variable risks, suggesting confounding factors.
Conclusions:
- Evidence strongly supports that menopausal therapy with low-dose conjugated estrogens (≤0.625 mg/d) does not elevate breast cancer risk.
- Higher ERT doses require further investigation due to significant risk variations.
- The findings provide reassurance for women using low-dose ERT for menopausal symptom management.